Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Immune Checkpoint Agents Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Immune Checkpoint Agents Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Anti-PD-L1 Drug
      • 1.3.3 Anti-PD-1 Drug
      • 1.3.4 CTLA4
    • 1.4 Market Segment by Application
      • 1.4.1 Global Immune Checkpoint Agents Market Share by Application (2019-2025)
      • 1.4.2 Lung Cancer
      • 1.4.3 Colorectal Cancer
      • 1.4.4 Breast Cancer
      • 1.4.5 Prostate Cancer
      • 1.4.6 Melanoma
      • 1.4.7 Blood Cancers
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Immune Checkpoint Agents Market Size
      • 2.1.1 Global Immune Checkpoint Agents Revenue 2014-2025
      • 2.1.2 Global Immune Checkpoint Agents Sales 2014-2025
    • 2.2 Immune Checkpoint Agents Growth Rate by Regions
      • 2.2.1 Global Immune Checkpoint Agents Sales by Regions 2014-2019
      • 2.2.2 Global Immune Checkpoint Agents Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Immune Checkpoint Agents Sales by Manufacturers
      • 3.1.1 Immune Checkpoint Agents Sales by Manufacturers 2014-2019
      • 3.1.2 Immune Checkpoint Agents Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Immune Checkpoint Agents Revenue by Manufacturers (2014-2019)
      • 3.2.2 Immune Checkpoint Agents Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Immune Checkpoint Agents Market Concentration Ratio (CR5 and HHI)
    • 3.3 Immune Checkpoint Agents Price by Manufacturers
    • 3.4 Key Manufacturers Immune Checkpoint Agents Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Immune Checkpoint Agents Market
    • 3.6 Key Manufacturers Immune Checkpoint Agents Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Anti-PD-L1 Drug Sales and Revenue (2014-2019)
      • 4.1.2 Anti-PD-1 Drug Sales and Revenue (2014-2019)
      • 4.1.3 CTLA4 Sales and Revenue (2014-2019)
    • 4.2 Global Immune Checkpoint Agents Sales Market Share by Type
    • 4.3 Global Immune Checkpoint Agents Revenue Market Share by Type
    • 4.4 Immune Checkpoint Agents Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Immune Checkpoint Agents Sales by Application

    6 United States

    • 6.1 United States Immune Checkpoint Agents Breakdown Data by Company
    • 6.2 United States Immune Checkpoint Agents Breakdown Data by Type
    • 6.3 United States Immune Checkpoint Agents Breakdown Data by Application

    7 European Union

    • 7.1 European Union Immune Checkpoint Agents Breakdown Data by Company
    • 7.2 European Union Immune Checkpoint Agents Breakdown Data by Type
    • 7.3 European Union Immune Checkpoint Agents Breakdown Data by Application

    8 China

    • 8.1 China Immune Checkpoint Agents Breakdown Data by Company
    • 8.2 China Immune Checkpoint Agents Breakdown Data by Type
    • 8.3 China Immune Checkpoint Agents Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Immune Checkpoint Agents Breakdown Data by Company
    • 9.2 Rest of World Immune Checkpoint Agents Breakdown Data by Type
    • 9.3 Rest of World Immune Checkpoint Agents Breakdown Data by Application
    • 9.4 Rest of World Immune Checkpoint Agents Breakdown Data by Countries
      • 9.4.1 Rest of World Immune Checkpoint Agents Sales by Countries
      • 9.4.2 Rest of World Immune Checkpoint Agents Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Bristol Myers Squibb
      • 10.1.1 Bristol Myers Squibb Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Immune Checkpoint Agents
      • 10.1.4 Immune Checkpoint Agents Product Introduction
      • 10.1.5 Bristol Myers Squibb Recent Development
    • 10.2 Merck
      • 10.2.1 Merck Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Immune Checkpoint Agents
      • 10.2.4 Immune Checkpoint Agents Product Introduction
      • 10.2.5 Merck Recent Development
    • 10.3 AstraZeneca
      • 10.3.1 AstraZeneca Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Immune Checkpoint Agents
      • 10.3.4 Immune Checkpoint Agents Product Introduction
      • 10.3.5 AstraZeneca Recent Development
    • 10.4 Roche
      • 10.4.1 Roche Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Immune Checkpoint Agents
      • 10.4.4 Immune Checkpoint Agents Product Introduction
      • 10.4.5 Roche Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Immune Checkpoint Agents Sales Channels
      • 11.2.2 Immune Checkpoint Agents Distributors
    • 11.3 Immune Checkpoint Agents Customers

    12 Market Forecast

    • 12.1 Global Immune Checkpoint Agents Sales and Revenue Forecast 2019-2025
    • 12.2 Global Immune Checkpoint Agents Sales Forecast by Type
    • 12.3 Global Immune Checkpoint Agents Sales Forecast by Application
    • 12.4 Immune Checkpoint Agents Forecast by Regions
      • 12.4.1 Global Immune Checkpoint Agents Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Immune Checkpoint Agents Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Immune Checkpoint Agents is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Immune Checkpoint Agents.

      This report studies the global market size of Immune Checkpoint Agents, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Immune Checkpoint Agents sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Bristol Myers Squibb
      Merck
      AstraZeneca
      Roche
      ...

      Market Segment by Product Type
      Anti-PD-L1 Drug
      Anti-PD-1 Drug
      CTLA4

      Market Segment by Application
      Lung Cancer
      Colorectal Cancer
      Breast Cancer 
      Prostate Cancer
      Melanoma
      Blood Cancers

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Immune Checkpoint Agents status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Immune Checkpoint Agents manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Immune Checkpoint Agents are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now